Home - Voyageur Pharmaceuticals

BUILDING NORTH AMERICA’S FIRST VERTICALLY INTEGRATED CONTRAST MEDIA SUPPLY CHAIN

The only North American company building a domestic, secure and vertically integrated contrast media drug solution at a cost structure no manufacturer can match.

VIEW OUR CORPORATE PRESENTATION

90%+

Cost Advantage^1,1.1

Total integration of primary ingredients produces unmatched gross margin potential on domestic soil.

200%

Market Growth by 2033²

One of the highest consumables in diagnosing disease, demand for contrast media continues to grow.

A $14 Billion Market by 2033

One of the highest consumables in diagnosing disease. Contrast media is necessary to create internal structure images of the body to diagnose cardiovascular disease, cancer, strokes and other major diseases.
Used In:

CT Scans
Fluoroscopy Imaging

Barium and iodine remain the undisputed clinical standard, making them essential and irreplaceable inputs for modern diagnostic imaging, with the market size anticipated to reach $14 billion by 2033².

Be the first to know as we advance to production

Same indispensable market A fundamentally different, secure supply chain.

Vertically Integrated. Domestically Secured.

A Barium Solution

100% ownership of the only known pharma-grade barium deposit in North America. PEA-confirmed production costs at $470/tonne vs. industry standard of $6,100-$11,600/tonne^1,1.1.

90%+

Cost Advantage^1,1.1

Licensed

Health Canada Barium Contrast Products

An Iodine Solution

Fully owned, patent-pending Mueller Process enables the first domestic pharmaceutical-grade iodine production. Extracts iodine from oilfield brine water currently discarded by the oil industry.

1st

North American Iodine Contrast Media Producer⁴

$2.35M

Nondilutive Funding (Bayer Offtake)

Feasibility Pipeline

Go-To-Market Timeline Forecast

Proven Innovation, Capital Markets Ready

“Capital is selective right now, and it should be. What got my attention with Voyageur is commercial revenue today, Bayer funding the iodine feasibility study, and a firm like Fluor doing the engineering, which is not a typical profile for a company this size. I joined the board because the business has de-risked well ahead of where the valuation sits, and with a cost structure that would be very difficult to match for any synthetic producer in a market this large, it has a credible path to leading the space rather than chasing it.”

Jeffry Kraws

Top 10 global pharma stock picker

fornearly 20 years, including #1 StarMine, 5-Star biotech & pharma ratings by StarMine; top-rated by Zacks

“From my decades-long experience as a risk manager, I see that the best-run organizations are those that manage reward and risk intentionally and thoughtfully to achieve valuable strategic objectives. Voyageur’s well-constructed project timelines and their sharp focus on internal and external validation of key processes reflect Voyageur’s risk-aware culture and commitment to resilient and sustainable product development and execution.“

Chris Van Buren

Former CRO at Edward Jones

($2T+ assets, 9M clients) and TIAA ($1T AUM, 4M+ clients), leading enterprise risk management

90%+

Cost Advantage1,1.1

200%

Market Growth by 20332

A $14 Billion Market by 2033

Be the first to know as we advance to production

Same indispensable market A fundamentally different, secure supply chain.

Vertically Integrated. Domestically Secured.

A Barium Solution

90%+

Licensed

An Iodine Solution

1st

$2.35M

Feasibility Pipeline

2022NI 43-101 PEA completed

Q3 2024Alberta Innovates $600K grant received

Q3 2024Human clinical testing completed and clinically accepted

Q3 2024Five Health Canada-licensed barium contrast products introduced

Q4 2026Frances Creek Pre-feasibility study

Q4 2026Iodine Drug Manufacturing FEL-3 study (internal)

Q1–Q2 2027Frances Creek Final feasibility study

Q2–Q3 2027Bayer Iodine Production Project FEL-3 study

Q3–Q4 2027Barium & Iodine Drug Manufacturing Facility, USA FEL-3 study

Go-To-Market Timeline Forecast

2028-29Frances Creek barite mine in full production

2028-29Bayer Iodine Production Project

2030Voyageur Iodine Contrast Drug Production

2030+Global Barium and Iodine Contrast Market Disruption

Proven Innovation, Capital Markets Ready

Jeffry Kraws

Top 10 global pharma stock picker

Chris Van Buren

Former CRO at Edward Jones

News

Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment

Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker

Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility

Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway

Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project

Voyageur Announces Closing of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption

Voyageur Announces Filing of Amended and Restated Offering Document

Voyageur Announces Update to Non-Brokered Life Offering

Voyageur Announces Shares for Debt Settlement and Stock Option Repricing

Voyageur Announces Non-Brokered Life Offering

Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects

Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU Grants, and Proposed Issuance of Securities for Debt

Voyageur Pharmaceuticals Announces Collaboration with Bayer

Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology

Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion

Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with Phalanx

Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion

Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform

Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics

Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million

Voyageur Advances Frances Creek Barite Project with Vast Engagement for Bulk Sample Permit

Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants

Voyageur Pharmaceuticals Signs Loi For Latin America Distribution Partnership Supporting Global Market Expansion

Voyageur And Altillion Forge Landmark Alliance To Establish NorthAmerica’s First Vertically Integrated Iodine Drug Supply Chain

Voyageur Enters Revenue Stage With First Commercial Sale of Barium Contrast Agents

Voyageur Pharmaceuticals Announces Appointment Of Ethan Mohan As Executive Vice President

Voyageur Pharmaceuticals Announces Changes To Board Of Directors And DSU Grant

Voyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study Results

Voyageur Pharmaceuticals Grants Deferred Share Units

Voyageur Completes Human Testing Of Barium Contrast Products And Prepares For Canadian Market Launch

Voyageur Pharmaceuticals Advances Frances Creek Project, Paving The Way For A Secure, Vertically Integrated Barium Contrast Product Line

Voyageur Clarifies Terms Of Previously Announced Agreement

Voyageur Pharmaceuticals Grants Deferred Share Units

Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes

Voyageur Advances MRI Drug Development Using Next-Generation Endohedral Fullerenes

Voyageur Receives $600k Grant From Alberta Innovates for Product Development

Voyageur Secures $687k of Additional Capital From Warrant Exercises

Voyageur Recaps Significant 2024 Achievements And Unveils Plans For Transformational 2025, Including Market Launch For Barium Suite Of Products And Advancement Of Iodine Suite

Voyageur Commences Testing Of Innovative Barium Contrast Product Line In Human Radiology Scans, Paving The Way for Near-Term Market Launch

Voyageur Pharmaceuticals Ltd. Signs Letter Of Intent With Global Contrast Imaging Company To Expand Market Reach And Product Portfolio

Voyageur Announces Closing Of Final Tranche Of Private Placement

Voyageur Announces Closing Of First Tranche Of Private Placement

Voyageur Announces Extension to Complete Proposed Private Placement

Voyageur Announces Proposed Private Placement

Voyageur Pharmaceuticals Grants Stock Options

Cost Advantage^1,1.1

Market Growth by 2033²